1-benzyl-4-(2-benzyloxy-phenyl)-piperidin-4-ol | 336882-79-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-benzyl-4-(2-benzyloxy-phenyl)-piperidin-4-ol
• 英文别名: 1-benzyl-4-(2-benzyloxyphenyl)-4-piperidinol；1-benzyl-4-(2-phenylmethoxyphenyl)piperidin-4-ol
• CAS: 336882-79-2
• 化学式: C₂₅H₂₇NO₂
• 分子量: 373.495
• InChiKey: COPPNYLMTSSDAQ-UHFFFAOYSA-N

物化性质

• 沸点：
  552.9±50.0 °C(Predicted)
• 密度：
  1.166±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  32.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-benzyl-4-(2-benzyloxy-phenyl)-piperidin-4-ol 在 palladium dihydroxide 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、405.3 kPa 条件下， 反应 6.0h， 以95%的产率得到4-hydroxy-4-(2-hydroxyphenyl)piperidine
  参考文献：
  名称：

  New .MU.-Opioid Receptor Agonists with Phenoxyacetic Acid Moiety.

  摘要：

  合成并评估了含有 4-羟基哌啶、哌啶和哌嗪分子的新型μ-阿片受体（MOR）激动剂，以寻找一种外周阿片类镇痛药。在合成的化合物中，[2-[1-[3-（N,N-二甲基氨基甲酰基）-3,3-二苯基丙基]-4-羟基哌啶-4-基]苯氧基]乙酸（8：在离体豚鼠回肠制剂中，具有苯氧乙酸和 4-羟基哌啶分子的 SS620 对 MOR 的激动效力最高，与同类型的 δ- 和 κ- 阿片受体（DOR 和 KOR）相比，它对中国仓鼠卵巢（CHO）-K1 细胞中表达的人类 MOR 也具有选择性。）此外，化合物 8 显示出的 MOR 激动剂活性是洛哌丁胺的 10 倍。此外，化合物 8 在大鼠体内筛选中显示出外周镇痛活性。

  DOI：

  10.1248/cpb.50.292
• 作为产物：
  描述：

  N-苄基哌啶酮 、 magnesium,phenylmethoxybenzene,bromide 以 四氢呋喃 为溶剂， 生成 1-benzyl-4-(2-benzyloxy-phenyl)-piperidin-4-ol
  参考文献：
  名称：

  New .MU.-Opioid Receptor Agonists with Phenoxyacetic Acid Moiety.

  摘要：

  合成并评估了含有 4-羟基哌啶、哌啶和哌嗪分子的新型μ-阿片受体（MOR）激动剂，以寻找一种外周阿片类镇痛药。在合成的化合物中，[2-[1-[3-（N,N-二甲基氨基甲酰基）-3,3-二苯基丙基]-4-羟基哌啶-4-基]苯氧基]乙酸（8：在离体豚鼠回肠制剂中，具有苯氧乙酸和 4-羟基哌啶分子的 SS620 对 MOR 的激动效力最高，与同类型的 δ- 和 κ- 阿片受体（DOR 和 KOR）相比，它对中国仓鼠卵巢（CHO）-K1 细胞中表达的人类 MOR 也具有选择性。）此外，化合物 8 显示出的 MOR 激动剂活性是洛哌丁胺的 10 倍。此外，化合物 8 在大鼠体内筛选中显示出外周镇痛活性。

  DOI：

  10.1248/cpb.50.292

文献信息

• [EN] (4-PHENYL-PIPERIDIN-1-YL)-[5-1H-PYRAZOL-4YL)-THIOPHEN-3-YL]-METHANONE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS DE (4-PHÉNYL-PIPÉRIDIN-1-YL)-[5-1H-PYRAZOL-4-YL)-THIOPHÉN-3-YL]-MÉTHANONE ET LEUR UTILISATION
  申请人：UNIV EDINBURGH

  公开号：WO2011033255A1

  公开（公告）日：2011-03-24

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)- [5-(1 H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 1 1 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

  本发明一般涉及治疗化合物领域。更具体地说，本发明涉及某些（4-苯基-哌啶-1-基）-[5-(1 H-吡唑-4-基)-噻吩-3-基]-甲酮化合物，其中包括抑制11β-羟基甾酮脱氢酶1（11β-HSD1）的作用。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物在体外和体内抑制11β-羟基甾酮脱氢酶1的用途；治疗通过抑制11β-羟基甾酮脱氢酶1而得到改善的疾病；治疗代谢综合征，其中包括2型糖尿病和肥胖等疾病，以及相关疾病，包括胰岛素抵抗、高血压、脂质紊乱和缺血性（冠状动脉）心脏病等心血管疾病；治疗轻度认知障碍和早期痴呆等中枢神经系统疾病，包括阿尔茨海默病等。
• 4-hydroxy-4-phenylpiperidine derivatives and pharmaceuticals containing the same
  申请人：SSP Co., LTD

  公开号：US06362203B1

  公开（公告）日：2002-03-26

  Described is a 4-hydroxy-4-phenylpiperidine derivative represented by the following formula (1): [wherein, R1 and R2 are the same or different and each independently represents a hydrogen atom, a lower alkyl, or the like, R3 represents a hydrogen atom or a group —(CR4R5)n—Y (in which, R4 and R5 each represents a hydrogen atom or a lower alkyl group, Y represents a group —COOR6, —CONR7R8, —OR9 or —OCOR10 (in which R6, R9 and R10 each independently represents a hydrogen atom, a lower alkyl group, or the like, R7 and R8 are the same or different and each independently represents a hydrogen atom, a lower alkyl group, or the like), and n stands for 1 to 6)], or salt thereof. The compound exhibits excellent peripheral analgesic action.

  描述了一种由以下式子（1）表示的4-羟基-4-苯基哌啶衍生物：[其中，R1和R2相同或不同，每个独立地表示氢原子、低碳基或类似物，R3表示氢原子或基团—(CR4R5)n—Y（其中，R4和R5各自表示氢原子或低碳基，Y表示基团—COOR6、—CONR7R8、—OR9或—OCOR10（其中，R6、R9和R10各自独立地表示氢原子、低碳基或类似物，R7和R8相同或不同，每个独立地表示氢原子、低碳基或类似物），n表示1到6）]，或其盐。该化合物表现出优异的周围镇痛作用。
• (4-Phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone Compounds and Their Use
  申请人：Webster Scott Peter

  公开号：US20120172393A1

  公开（公告）日：2012-07-05

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

  本发明涉及治疗化合物领域。更具体地说，本发明涉及某些(4-苯基哌啶-1-基)-[5-(1H-吡唑-4-基)-噻吩-3-基]-甲酮化合物，其中包括抑制11β-羟化类固醇脱氢酶1型(11β-HSD1)的化合物。本发明还涉及包含此类化合物的制药组合物的使用，以及在体外和体内使用此类化合物和组合物以抑制11β-羟化类固醇脱氢酶1型；治疗由抑制11β-羟化类固醇脱氢酶1型改善的疾病；治疗代谢综合征，包括2型糖尿病和肥胖症等疾病，以及相关疾病，包括胰岛素抵抗、高血压、脂质代谢异常和心血管疾病，如缺血性(冠状)心脏病；治疗轻度认知障碍和早期痴呆等中枢神经系统疾病，包括阿尔茨海默病等。
• (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use
  申请人：Webster Scott Peter

  公开号：US08642621B2

  公开（公告）日：2014-02-04

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

  本发明涉及治疗化合物领域。更具体地说，本发明涉及某些（4-苯基哌啶-1-基）-[5-(1H-吡唑-4-基)-噻吩-3-基]-甲酮化合物，这些化合物在其他方面抑制11β-羟化类固醇脱氢酶1型（11β-HSD1）。本发明还涉及包含这些化合物的药物组合物，以及使用这些化合物和组合物，在体内外抑制11β-羟化类固醇脱氢酶1型；治疗通过抑制11β-羟化类固醇脱氢酶1型改善的疾病；治疗代谢综合征，包括2型糖尿病和肥胖症等疾病，以及相关疾病，包括胰岛素抵抗、高血压、脂质代谢紊乱和缺血性（冠状动脉）心脏病等；治疗中枢神经系统疾病，如轻度认知障碍和早期痴呆，包括阿尔茨海默病等。
• 4-hydroxy-4-phenylpiperidine derivatives having -opioid agonist activity and pharmaceuticals containing the same
  申请人：SSP Co., Ltd.

  公开号：EP1097924A1

  公开（公告）日：2001-05-09

  Described is a 4-hydroxy-4-phenylpiperidine derivative represented by the following formula (1): [wherein, R1 and R2 are the same or different and each independently represents a hydrogen atom, a lower alkyl, or the like, R3 represents a hydrogen atom or a group -(CR4R5)n-Y (in which, R4 and R5 each represents a hydrogen atom or a lower alkyl group, Y represents a group -COOR6, -CONR7R8, -OR9 or -OCOR10 (in which R6, R9 and R10 each independently represents a hydrogen atom, a lower alkyl group, or the like, R7 and R8 are the same or different and each independently represents a hydrogen atom, a lower alkyl group, or the like), and n stands for 1 to 6)], or salt thereof. The compound exhibits excellent peripheral analgesic action.

  所述的是由下式(1)代表的 4-羟基-4-苯基哌啶衍生物： [其中，R1 和 R2 相同或不同，各自独立地代表氢原子、低级烷基或类似物，R3 代表氢原子或基团-(CR4R5)n-Y（其中，R4 和 R5 各自代表氢原子或低级烷基，Y 代表基团-COOR6、-CONR7R8、-OR9或-OCOR10（其中，R6、R9和R10各自独立地代表氢原子、低级烷基或类似基团，R7和R8相同或不同且各自独立地代表氢原子、低级烷基或类似基团），n代表1至6）]，或其盐。 该化合物具有良好的外周镇痛作用。